Ovarian hyperandrogenism

Ovarian hyperandrogenism is an endocrine condition in which the ovary becomes the main source of androgen excess, with increased production of testosterone and other ovarian androgens and the consequent development of clinical manifestations such as hirsutism, acne, androgenetic alopecia, ovulatory dysfunction and, in more severe presentations, signs of virilization. It does not represent a single disease, but rather a pathophysiological category encompassing functional forms, particularly those within the spectrum of polycystic ovary syndrome, and nonfunctional forms such as ovarian hyperthecosis and rare androgen-secreting ovarian tumors. The central issue is therefore to identify the ovarian source of androgen excess and distinguish it from adrenal, iatrogenic or peripheral causes.

The clinical relevance of the condition depends not only on its dermatological and reproductive effects, but also on its metabolic and prognostic significance. In functional forms, androgen excess is closely associated with insulin resistance, menstrual cycle abnormalities, infertility and cardiometabolic risk. In severe or rapidly progressive forms, however, the clinical priority is the prompt recognition of an organic ovarian disorder, because intense androgen overproduction, particularly when associated with recent virilization or onset after menopause, may indicate a structural ovarian disease requiring specific treatment.

The epidemiology of ovarian hyperandrogenism primarily reflects the prevalence of its underlying causes. In clinical practice among women of reproductive age, the vast majority of cases are functional, particularly polycystic ovary syndrome, which is the most common cause of androgen excess in adolescent and adult women. Estimates of PCOS prevalence vary according to the diagnostic criteria used and the population studied, but the syndrome affects a substantial proportion of women of reproductive age. Similarly, a very high proportion of women presenting with clinical or biochemical signs of hyperandrogenism fall within the PCOS spectrum, which explains why ovarian hyperandrogenism is often initially approached as a functional syndrome unless evidence suggests otherwise.

The distribution changes with age. Functional forms predominate during adolescence and early reproductive life and are characterized by a gradual onset of hirsutism, acne and menstrual irregularities. During perimenopause and particularly postmenopause, however, the relative contribution of nonfunctional ovarian forms increases, especially ovarian hyperthecosis and androgen-secreting tumors. This does not mean that PCOS disappears after menopause, because the hyperandrogenic phenotype may persist over time, but the development of new postmenopausal hyperandrogenism shifts clinical attention toward organic ovarian or adrenal causes, particularly when the presentation is severe or rapidly progressive.

Regarding risk factors, family history, genetic predisposition, neuroendocrine characteristics, visceral obesity and insulin resistance are relevant in functional ovarian hyperandrogenism. Obesity is not essential, but when present it amplifies the androgenic phenotype through hyperinsulinemia, reduced SHBG concentrations and enhanced theca cell steroidogenesis. Even patients of normal weight, however, may have intrinsic abnormalities of ovarian steroidogenesis that make ovarian tissue more likely to produce excessive amounts of androgens in response to gonadotropin stimulation.

In organic forms, risk depends less on environmental factors and more on the development of a stromal or neoplastic ovarian disorder. Hyperthecosis is typically observed in perimenopausal or postmenopausal women with progressive androgenization and often severe metabolic impairment, including type 2 diabetes, central obesity and acanthosis nigricans. Androgen-secreting ovarian tumors are rare, but their importance is disproportionate to their frequency because they may present with markedly elevated testosterone levels and overt virilization.

There is also a profile of clinical vulnerability related to the duration of androgen exposure. Chronic androgen excess, even when it is not rapidly progressive, has cumulative effects on the skin, reproductive system, glucose metabolism and body composition. The epidemiology of ovarian hyperandrogenism should therefore be interpreted not only as the distribution of etiologies, but also as the epidemiology of long term harm, including anovulatory infertility, endometrial hyperplasia caused by chronic anovulation, worsening metabolic risk and a substantial psychological burden.

Finally, the context of presentation has epidemiological and diagnostic value. Pubertal or peripubertal onset, slow progression, chronic menstrual irregularities and moderate hyperandrogenism suggest a functional form. Conversely, androgenization developing over a few months, clitoromegaly, a deeper voice, rapid increase in muscle mass or onset after menopause increase the pretest probability of an organic ovarian source and require a faster and more detailed assessment.

Understanding ovarian hyperandrogenism requires consideration of the physiology of ovarian steroidogenesis. In the normal ovary, the theca cell produces androgens mainly in response to LH stimulation, whereas the granulosa cell, under FSH control, converts them into estrogens through aromatase. This balance allows orderly folliculogenesis, selection of the dominant follicle and coordinated steroid secretion. Ovarian hyperandrogenism develops when theca cell androgen production becomes excessive relative to the capacity for estrogen conversion, or when intraovarian signals promote steroidogenesis that is persistently shifted toward androgen production.

From an etiological perspective, the most common form is functional ovarian hyperandrogenism, which in most cases corresponds to the endocrine core of PCOS. In this setting, the ovary has an intrinsic predisposition for theca cells to respond excessively to gonadotropin stimulation, resulting in increased androgen steroidogenesis. This abnormality is often amplified by hyperinsulinemia, which acts as a gonadotropin cofactor, enhances the action of LH, promotes theca cell steroidogenesis and reduces hepatic SHBG production, thereby increasing the free and biologically active fraction of testosterone. The final result is a self-perpetuating cycle in which elevated androgens, impaired follicular maturation and metabolic dysfunction reinforce one another.

At the molecular level, ovarian androgen steroidogenesis involves the transport of cholesterol into mitochondria and activation of enzymes such as CYP11A1, 3β-HSD and particularly CYP17A1, which has both 17α-hydroxylase and 17,20-lyase activity. These pathways are functionally overactive in functional hyperandrogenic forms, partly because of increased sensitivity of theca cells to LH and insulin. At the same time, granulosa cell function and aromatization become relatively inadequate, so a greater proportion of steroid substrate remains androgenic instead of being converted into estrogens. This intrafollicular imbalance disrupts the environment required for dominant follicle selection.

The most characteristic pathophysiological consequence is arrested folliculogenesis. Excess androgens promote initial follicular recruitment but impair terminal maturation, interfere with selection of the dominant follicle and are associated with persistence of multiple small antral follicles. From an endocrine perspective, failure to ovulate results in the absence of adequate luteal progesterone production, exposing the endometrium to unopposed estrogens or irregular hormonal patterns. This leads to menstrual abnormalities, irregular bleeding, anovulatory infertility and a risk of endometrial hyperplasia when the dysfunction persists over time.

In ovarian hyperthecosis, the mechanism differs in both intensity and histological basis. The disorder does not consist solely of abnormal functional regulation of the follicle, but involves luteinized theca cells dispersed throughout hyperplastic ovarian stroma, which are capable of producing androgens more intensely and relatively autonomously. This condition occurs mainly during perimenopause and postmenopause, when the gonadotropin and metabolic environment creates conditions favorable to stromal steroidogenesis. Clinically, it often causes elevated testosterone, more pronounced virilization than PCOS and a close association with severe insulin resistance and metabolic syndrome.

Androgen-secreting ovarian tumors represent the third major etiopathogenetic category. In most cases, they arise from sex cord and stromal neoplasms, including Leydig cell tumors, steroid cell tumors and Sertoli-Leydig cell tumors. In this setting, androgen excess is sustained by a steroidogenically active neoplastic clone, often producing rapid clinical progression, markedly elevated testosterone levels and evident virilization. The distinguishing pathophysiological feature is that androgen excess no longer results from amplification of abnormal ovarian physiology, but from autonomous tumor production.

The systemic effects of ovarian hyperandrogenism are not limited to the ovary. In the skin, androgens increase pilosebaceous activity, promote the conversion of vellus hair into terminal hair in androgen-dependent areas and cause follicular miniaturization on the scalp. Metabolically, androgens promote visceral adiposity, worsen insulin resistance, alter glucose and lipid profiles and increase cardiometabolic risk. At the neuroendocrine level, they may alter pulsatile gonadotropin secretion, reinforcing LH predominance and perpetuating the reproductive disorder. Ovarian hyperandrogenism should therefore be understood as a systemic syndrome that originates in the ovary but pathologically reshapes the entire female reproductive and metabolic axis.

The clinical presentation of ovarian hyperandrogenism depends on the patient’s age, the intensity of androgen excess, the speed of onset and the underlying cause. Functional forms often follow a slow and progressive course, with symptoms beginning during adolescence or early adulthood and initially being interpreted mainly as a dermatological or gynecological problem. In organic forms, particularly tumors, progression may be much more rapid and culminate in overt virilization.

In the medical history, the most common symptom is hirsutism, defined as the growth of terminal hair in androgen-sensitive areas such as the chin, upper lip, intersternal region, linea alba and inner thighs. Persistent acne, seborrhea and female androgenetic alopecia may accompany it, particularly when cutaneous sensitivity to androgens is high. The chronology of symptoms is highly informative: hirsutism present for years with slow progression suggests a functional form, whereas rapid worsening over a few months increases suspicion of an ovarian secretory lesion.

A second clinical domain is reproductive function. Patients with functional ovarian hyperandrogenism frequently report oligomenorrhea, irregular menstrual cycles, secondary amenorrhea or subfertility caused by anovulation. These features result from disorganized folliculogenesis and the absence of regular ovulation. In some patients, menstrual dysfunction is the first manifestation, whereas cutaneous signs develop or are recognized only later. In severe organic forms, however, menstrual impairment may rapidly become associated with signs of intense androgenization.

The physical examination should systematically assess signs of androgen excess, chronic anovulation and metabolic dysfunction. In addition to evaluating the terminal hair score, clinicians should assess inflammatory acne, frontoparietal hair thinning, body mass index, body fat distribution, waist circumference and the presence of acanthosis nigricans, which suggests significant hyperinsulinemia. Many patients with a PCOS phenotype have central adiposity and signs of insulin resistance, although clinically significant androgen excess may also occur in patients of normal weight.

Signs of virilization have a different clinical significance from uncomplicated hyperandrogenism. Clitoromegaly, deepening of the voice, marked increase in muscle mass, breast regression and rapid development of severe alopecia are not typical of mild or moderate functional hyperandrogenism and require investigation for an organic ovarian cause, particularly hyperthecosis or an androgen-secreting tumor. An unusually increased libido or rapid change in body habitus may also provide useful clinical clues.

The presentation in postmenopausal women requires particular attention. Mild facial hair growth may accompany the physiological decline in estrogen levels, but progressive hirsutism, the development of substantial alopecia or true signs of virilization should not be considered normal. In this setting, the likelihood of a pathological ovarian source is much higher than during reproductive life, and assessment should proceed rapidly with the aim of localizing the source of androgen production.

Finally, ovarian hyperandrogenism has a marked effect on quality of life. Hirsutism, acne and alopecia may cause psychological distress, social isolation, body image disturbance and anxiety or depressive symptoms. This burden is not incidental but an integral component of the disorder because it affects adherence, healthcare seeking and perception of therapeutic benefit. An accurate clinical assessment should therefore integrate endocrine signs, reproductive function, metabolic profile and psychosocial impact.

Ovarian hyperandrogenism should be suspected when a woman presents with clinical or biochemical androgenization compatible with a gonadal source. The most typical setting is a patient with hirsutism associated with menstrual irregularities, persistent acne, anovulation or infertility, particularly when onset occurred during adolescence or early adulthood. In these cases, the probability of a functional ovarian form is high, but the suspicion should still lead to a systematic assessment that excludes adrenal, pharmacological and neoplastic causes.

The presence of red flags radically changes the clinical reasoning. Rapid worsening of symptoms, the development of virilization, severely increased androgen levels, onset after menopause or a presentation without the typical history of chronic ovulatory dysfunction should raise suspicion of a nonfunctional ovarian cause. In these situations, the issue is no longer simply to confirm hyperandrogenism, but to promptly determine whether the ovary contains a secretory lesion or androgenically active hyperplastic stroma.

Suspicion should be strengthened by the combination of clinical signs and the endocrine pattern. Elevated testosterone with no marked increase in DHEAS more readily suggests an ovarian origin, although this finding alone is not diagnostic. Similarly, a woman with clinical hyperandrogenism and chronic oligo-anovulation has a very different profile from an eumenorrheic patient with mild isolated hirsutism, in whom the diagnostic algorithm may be less intensive and more targeted.

Suspicion of an ovarian cause should be even higher during perimenopause and postmenopause. At this stage of life, the new onset of clinically significant androgen excess cannot automatically be attributed to endocrine aging. Rapid androgenetic alopecia, progressive hirsutism, deepening of the voice or increased muscle mass require immediate consideration of ovarian hyperthecosis and an androgen-secreting tumor among the primary diagnostic possibilities.

Certain metabolic contexts also help guide suspicion. Visceral obesity, acanthosis nigricans, impaired glucose metabolism and a history of PCOS make functional ovarian hyperandrogenism more likely. Conversely, intense virilization in a woman without previous hyperandrogenism, with rapid progression and a possible ovarian mass on imaging, shifts the balance toward an organic disorder. Clinical suspicion should therefore never be based on a single symptom, but on the consistency between speed of onset, severity, age and hormonal profile.

Finally, suspicion should also be maintained when apparently isolated dermatological manifestations are present. Severe treatment-resistant acne, early androgenetic alopecia or hirsutism dismissed as constitutional may be the initial presentation of a broader endocrine disorder. When clinical signs are modest, menstrual, reproductive and metabolic history becomes decisive in determining whether the presentation represents an isolated cosmetic concern or the early expression of clinically relevant ovarian hyperandrogenism.

The diagnosis of ovarian hyperandrogenism requires an orderly pathway that confirms androgen excess, assesses its severity and distinguishes a functional ovarian source from an organic ovarian cause or an extragonadal origin. The first level of assessment is clinical and laboratory based. The consultation should document the type of androgenic manifestations, their temporal progression, the presence of menstrual irregularities, fertility history, interfering medications and signs of virilization. Biochemically, the most useful measurement is total testosterone, ideally assessed using a reliable high sensitivity method, because commonly used immunoassays may be insufficiently accurate at the low or moderately increased concentrations found in women.

In addition to testosterone, the initial profile generally includes SHBG, free testosterone or the free androgen index when appropriate, androstenedione and DHEAS, which is particularly useful for assessing the adrenal contribution. In women with oligomenorrhea or amenorrhea, the diagnostic workup should also include prolactin, TSH, gonadotropins and morning 17-hydroxyprogesterone to exclude nonclassic congenital adrenal hyperplasia, together with targeted testing when the clinical presentation suggests Cushing syndrome or other endocrinopathies. The significance of biochemical testing is not merely confirmatory, but also helps determine etiology: mild or moderate androgen excess with a long clinical history and chronic ovulatory dysfunction is much more consistent with a functional ovarian form, whereas a marked increase in testosterone with rapid progression requires early imaging.

In the absence of universally accepted official diagnostic criteria for ovarian hyperandrogenism as a single entity, endocrine and gynecological endocrinology guidelines indicate that diagnostic assessment should demonstrate the presence of androgen excess, exclude nonovarian causes and localize the source of hypersecretion through imaging and clinical contextualization.

Diagnostic assessment of ovarian hyperandrogenism

• Confirmation of androgen excess through measurement of total testosterone, assessment of the free fraction or SHBG and, when useful, androstenedione and DHEAS using reliable methods.
• Exclusion of the main alternative diagnoses through medication history, 17-hydroxyprogesterone, prolactin, TSH and targeted investigations based on clinical suspicion.
• Assessment of the probability of a functional or organic ovarian source according to age, speed of progression, degree of virilization and severity of the biochemical abnormality.
• Pelvic imaging, initially with transvaginal ultrasound when feasible, supplemented by pelvic MRI when ultrasound findings are negative or uncertain but clinical and biochemical suspicion remains high.

In women of reproductive age with suspected PCOS, diagnosis follows specific official criteria. The 2023 international guideline recommends using the revised Rotterdam criteria, according to which diagnosis in adults requires two of the following: clinical or biochemical hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology, after exclusion of other causes. An important practical point is that when menstrual irregularities and hyperandrogenism coexist, ovarian ultrasound is not required to establish a diagnosis of PCOS, although it remains useful in many cases for morphological characterization and differential diagnosis.

The differential diagnosis is central to clinical reasoning. An ovarian origin must be distinguished from an adrenal source, iatrogenic hyperandrogenism, hyperprolactinemia, thyroid dysfunction, nonclassic congenital adrenal hyperplasia and conditions associated with cortisol excess. A very high DHEAS concentration, particularly when associated with rapid clinical progression, supports investigation of the adrenal glands. Markedly increased testosterone with a DHEAS concentration that is not proportionally elevated points more strongly toward the ovary. In postmenopausal women, inhibin B may be useful in selected settings when a stromal or sex cord tumor is suspected.

Imaging is decisive when the phenotype is inconsistent with an uncomplicated functional disorder. Transvaginal ultrasound is the first investigation used to identify enlarged ovaries, suggestive stromal patterns, nodules or masses. However, small androgen-secreting tumors may not be detected by ultrasound, particularly in postmenopausal women or when lesions are very small. In these situations, pelvic magnetic resonance imaging improves diagnostic sensitivity. When conventional imaging is also negative but clinical suspicion remains strong, referral to a specialist center and, in selected cases, selective venous sampling may be required.

The definitive diagnosis of an organic ovarian form is often histological and is obtained after surgical treatment. In clinical practice, the diagnosis of ovarian hyperandrogenism is therefore often an integrated one, in which biochemical results, imaging, clinical chronology and menopausal status converge to establish the most probable etiology and guide treatment. The objective is not merely to label the disorder, but to rapidly distinguish patients with a functional form requiring long term management from those with a pathological ovarian source requiring definitive treatment.

The classification of ovarian hyperandrogenism has primarily practical value because it links the severity of the presentation, the underlying cause and the therapeutic strategy. The first distinction separates functional forms from organic forms. Functional forms mainly include PCOS and related patterns of ovarian hyperandrogenism without evidence of a tumor, in which androgen excess is sustained by dysregulation of theca cell steroidogenesis and its interaction with insulin resistance and the gonadotropin axis. Organic forms include ovarian hyperthecosis and androgen-secreting tumors.

Functional forms may be further divided into predominantly reproductive phenotypes, in which oligo-anovulation and infertility predominate, and predominantly metabolic phenotypes, in which androgen excess is associated with visceral obesity, impaired glucose metabolism and high cardiometabolic risk. This distinction is not merely descriptive because it guides treatment and determines the priority of therapeutic objectives. A patient seeking pregnancy requires a different pathway from a patient whose main concern is controlling hirsutism, acne and metabolic risk.

Ovarian hyperthecosis represents an intermediate form between a functional disorder and a structural stromal disease. It is a benign but clinically aggressive condition, often characterized by more intense androgenization, elevated testosterone, severe insulin resistance and onset during perimenopause or postmenopause. Unlike classic PCOS, diffuse stromal involvement and luteinization of theca cells make the condition more severe, persistent and less easily controlled using conservative medical strategies alone.

Androgen-secreting ovarian tumors constitute the rare category with the greatest diagnostic impact. Severity depends not only on the oncological nature of the lesion, which may vary, but also on the speed with which the endocrine presentation develops. Progression over a few months, with virilization and markedly elevated testosterone, should prompt consideration of this category until it has been convincingly excluded. From a classification perspective, these lesions mainly include sex cord and stromal tumors with steroidogenic differentiation.

Another useful classification criterion concerns clinical severity. Mild forms present with acne or modest hirsutism without virilization, moderate forms have a substantial dermatological and reproductive impact, and severe forms involve clitoromegaly, deepening of the voice, marked alopecia, amenorrhea and severe metabolic abnormalities. This grading is not only descriptive, but also indicates the probability of a nonfunctional cause and the need for accelerated investigation.

Finally, classification should take the woman’s biological stage into account. Ovarian hyperandrogenism in an adolescent raises specific diagnostic problems because pubertal physiology may mimic certain aspects of PCOS and requires caution before establishing a permanent diagnosis. During reproductive life, classification is based mainly on distinguishing functional from organic forms. After menopause, however, any new clinically significant androgenization should be considered potentially pathological until the source has been localized, because the relative contribution of hyperthecosis and tumors becomes much greater than in younger women.

Treatment of ovarian hyperandrogenism depends critically on the etiology, age, desire for pregnancy, severity of clinical signs and metabolic profile. In functional forms, the objectives are to reduce androgen excess, restore orderly ovulatory function when possible, protect the endometrium and manage metabolic risk. In organic forms, treatment must eliminate the pathological ovarian source. The first therapeutic decision therefore concerns not which medication to choose, but whether the presentation is compatible with a chronic condition requiring medical management or with a disorder requiring surgery.

In patients with functional ovarian hyperandrogenism who are not seeking pregnancy, combined oral contraceptives are a cornerstone of treatment. By reducing gonadotropin secretion, increasing SHBG and limiting the availability of free androgens, they improve hirsutism, acne and menstrual regularity. The most recent recommendations for PCOS identify combined contraceptives as an effective option for menstrual irregularities and hyperandrogenism, with selection of the preparation guided mainly by the patient’s risk profile and tolerability rather than by clear evidence that one specific combination is superior to all others.

When the cosmetic response is inadequate, or when hirsutism is the predominant symptom, antiandrogens such as spironolactone may be added in the presence of adequate contraception, because the teratogenic risk makes antiandrogen monotherapy inappropriate in potentially fertile women without contraceptive protection. Improvement in terminal hair growth requires several months because treatment does not immediately remove hair that has already developed, but gradually reduces androgenic stimulation of the follicles. Realistic management therefore also includes cosmetic and laser procedures, which complement but do not replace endocrine control.

Treatment of the metabolic component is an integral part of care. Lifestyle intervention, weight reduction when indicated and management of insulin resistance have a direct rationale because they reduce hyperinsulinemia, decrease amplification of ovarian steroidogenesis and improve ovulation and the cardiometabolic profile. Metformin is particularly useful in patients with PCOS and excess weight or metabolic abnormalities, with its greatest benefit involving metabolic outcomes and, in some patients, menstrual regularity. It does not, however, replace antiandrogen treatment when control of hirsutism is the primary concern.

When the objective is fertility, the strategy changes. In women with anovulation caused by PCOS, the most recent guidelines recommend letrozole as the first line pharmacological treatment for ovulation induction when no other infertility factors are present. Clomiphene and metformin retain a role in specific settings, but the main objective is to restore effective ovulation rather than merely suppress hyperandrogenism. In these pathways, treatment should be coordinated with assessment of the metabolic profile, reproductive age, duration of infertility and other factors affecting the couple.

In ovarian hyperthecosis, medical control may be partial or temporary, but definitive treatment is often surgical, particularly in postmenopausal women or those with marked androgenization and persistently elevated testosterone. Removal of the ovaries eliminates the androgen source and produces rapid biochemical resolution, although certain clinical signs, such as deepening of the voice, may be only partially reversible. In patients who cannot undergo surgery or are awaiting definitive treatment, medical suppression strategies may be used, but their purpose is bridging or endocrine palliation rather than structural resolution.

Androgen-secreting ovarian tumors generally require surgical treatment, adapted according to age, fertility wishes, tumor type and stage. In these cases, surgery is both therapeutic and diagnostic because it permits histological confirmation of the lesion. Normalization of testosterone after removal is an important indicator that the etiological assessment was correct. In the small number of cases in which the oncological nature or histological type requires it, treatment may be extended to surgical staging and subsequent dedicated oncological strategies.

In all phenotypes, treatment should include realistic counselling regarding timing and objectives. Menstrual cycle regulation may occur before improvement in hirsutism. Acne and seborrhea respond more rapidly than terminal hair, whereas fertility and metabolism require dedicated pathways. Effective treatment of ovarian hyperandrogenism is therefore not a single medication, but a personalized strategy that begins with the androgen source, establishes the clinical priority and integrates endocrine, reproductive and metabolic management and, when necessary, surgery.

Follow-up of ovarian hyperandrogenism aims to assess symptom control, monitor the hormonal profile, prevent reproductive and metabolic complications and promptly identify any indication for renewed diagnostic evaluation. The frequency of follow-up depends on the cause. In functional forms, monitoring is generally continuous and multidimensional, whereas after surgical treatment it is primarily intended to confirm biochemical resolution and manage long term outcomes.

In patients with PCOS or related functional forms, monitoring should include the menstrual cycle, progression of hirsutism, acne and alopecia, body weight, waist circumference and metabolic parameters. Repeated measurement of androgens alone is insufficient because the cutaneous clinical response is slow and quality of life may improve or worsen independently of small biochemical changes. It is also important to assess treatment adherence, adverse effects of contraceptives or antiandrogens and endometrial protection in patients who remain anovulatory.

Metabolic follow-up is particularly important because functional ovarian hyperandrogenism is frequently associated with insulin resistance, impaired glucose tolerance, type 2 diabetes, dyslipidemia and increased cardiovascular risk. Fasting glucose, glycated hemoglobin or an oral glucose tolerance test when indicated, lipid profile and blood pressure should be incorporated into periodic monitoring. In many patients, dermatological improvement does not automatically coincide with normalization of metabolic risk, so a strategy focused solely on cosmetic concerns would be inadequate.

In patients undergoing treatment for infertility, follow-up should document ovulation, response to induction, the risk of multiple pregnancy when relevant and the presence of other infertility factors not attributable to hyperandrogenism. When pregnancy is not being sought, monitoring should instead ensure that chronic anovulation does not result in prolonged unopposed endometrial exposure. In this respect, follow-up concerns not only visible symptoms, but also prevention of the silent consequences of ovulatory dysfunction.

After surgical treatment of hyperthecosis or an androgen-secreting tumor, follow-up assesses the decline in testosterone, regression of clinical signs and the absence of persistence or recurrence. Certain signs, such as acne and seborrhea, improve relatively quickly. Others, such as long standing hirsutism or deepening of the voice, may regress only partially. In neoplastic forms, subsequent surveillance depends on the histological type and specific gynecological oncology protocols.

An often underestimated aspect is psychological and quality of life monitoring. Body image disturbance, low self-esteem, anxiety and depression are common among patients with chronic androgen excess. Follow-up should therefore assess not only whether hair growth or testosterone levels have decreased, but also whether the patient perceives a meaningful improvement in daily life. This approach improves adherence, treatment persistence and the appropriateness of therapeutic modifications.

Finally, follow-up should remain dynamic. A patient initially classified as having a functional form who subsequently develops rapid virilization, marked worsening or an unexpected increase in testosterone should be reassessed for a possible organic form. Monitoring therefore serves not only to confirm that treatment is progressing appropriately, but also to detect changes in the clinical trajectory that require a new differential diagnosis.

The prognosis of ovarian hyperandrogenism depends essentially on the cause. In functional forms, particularly those attributable to PCOS, the prognosis for survival is good, but the disorder tends to be chronic and requires long term management. The main concern is not mortality, but the cumulative burden of reproductive, metabolic, dermatological and psychological consequences. When the condition is recognized early and treated consistently with the patient’s objectives, symptom control and reduction of long term risk are generally satisfactory.

The most common complications involve ovulatory function and the endometrium. Chronic anovulation causes infertility, persistent menstrual irregularities and endometrial exposure that is not adequately counterbalanced by progesterone. Over time, this may lead to endometrial hyperplasia and an increased risk of endometrial disease, particularly in patients with prolonged amenorrhea or untreated irregular bleeding. Endometrial protection is therefore a prognostic component of care, not merely a symptomatic intervention.

Metabolic complications are equally important. Insulin resistance, central obesity, impaired glucose tolerance, type 2 diabetes, dyslipidemia and hepatic steatosis are more common in functional hyperandrogenic forms, particularly when visceral obesity and a high androgen burden coexist. Hyperandrogenism is not simply a cosmetic marker, but an active component of a broader metabolic syndrome, so long term prognosis also depends on the ability to control body weight, metabolism and cardiovascular risk factors.

The dermatological component may leave persistent consequences. Untreated chronic hirsutism tends to become established because androgen-stimulated hair follicles undergo stable conversion to terminal hair. Androgenetic alopecia may become difficult to reverse when follicular miniaturization persists. Cosmetic prognosis therefore improves with early treatment and worsens when the patient is assessed only after years of untreated androgen excess.

In ovarian hyperthecosis, the prognosis after definitive treatment is generally good from an endocrine perspective, although preexisting metabolic complications may persist and require independent treatment. In androgen-secreting tumors, prognosis depends on the histological type, extent of disease and timeliness of diagnosis. From an endocrine perspective, removal of the lesion often produces rapid biochemical normalization, but the overall prognosis remains linked to the biological behavior of the neoplasm.

Finally, a cross-cutting and frequently underestimated complication is impairment of quality of life. Body image distress, social stigma, depression, anxiety and relational or sexual difficulties may persist even when hormonal status improves, particularly when the clinical condition has been prolonged and severe. The prognosis of ovarian hyperandrogenism should therefore not be measured solely in terms of testosterone levels or menstrual regularity, but also in terms of functional, reproductive, metabolic and psychosocial recovery over the medium and long term.